Trailing-twelve-month (TTM) revenue is $389.32 Million with a year-over-year growth of +26.19%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $122,060,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $47,709,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $106,506,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $113,041,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $389,316,000 |
Current P/S: $601,660,515 market capitalization ÷ $389,316,000 TTM revenue = 1.55x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:49:53.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $113.04M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:51:52.049Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Collaborative Arrangement Co Promotion Agreement | $4M | N/A | N/A | N/A | N/A | N/A |
| Collaborative Arrangement Collaboration Agreements | $32M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Canada and Mexico | N/A | $3M | $3M | N/A | N/A | N/A |
| Canada And Mexico | $2M | N/A |
$389.32M
$389.32 Million
+26.19%
vs. $308.52M a year ago (TTM)
(1.18%)
5 Year compound annual growth rate
1 Year
+26.19%
3 Year
(3.05%)
5 Year
(1.18%)
10 Year
+6.20%
15 Year
+15.08%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $296.15M | ($55.26M) | (15.72%) |
| 2024 | $351.41M | ($91.33M) | (20.63%) |
| 2023 | $442.74M | +$32.14M | +7.83% |
| 2022 | $410.60M | ($3.16M) | (0.76%) |
| 2021 | $413.75M | +$24.23M | +6.22% |
| 2020 |
TTM Growth
+26.19%
3-Year CAGR
(3.05%)
5-Year CAGR
(1.18%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:51:52.049Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| N/A |
| N/A |
| Collaborative Arrangement Collaboration And License Agreements | $700,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Collaborative Arrangement Collaboration And License Agreements Upfront Fee | $10M | N/A | N/A | N/A | N/A | N/A |
|---|
| Collaborative Arrangement Promotion Agreement | $4M | N/A | N/A | N/A | N/A | N/A |
|---|
| Collaborative Arrangement Transition Services Agreement | $600,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Collaborative arrangement, co-promotion agreements | N/A | $2M | $2M | $2M | $2M | N/A |
|---|
| Collaborative arrangement, collaboration and license agreements | N/A | $743,000 | $635,000 | $2M | $2M | $2M |
|---|
| Collaborative arrangement, other agreements | N/A | $2M | $2M | $2M | $734,000 | $87,000 |
|---|
| Collaborative Arrangements | N/A | N/A | N/A | N/A | N/A | $296M |
|---|
| Collaborative arrangements revenue | N/A | $413M | $411M | $443M | $351M | N/A |
|---|
| Royalty | $100,000 | N/A | N/A | $2M | $400,000 | $300,000 |
|---|
| Sale of active pharmaceutical ingredient | N/A | $969,000 | N/A | N/A | N/A | N/A |
|---|
| N/A |
| N/A |
| N/A |
| Europe | $2M | N/A | N/A | N/A | N/A | N/A |
|---|
| Europe and Other | N/A | $3M | $2M | $3M | $3M | $4M |
|---|
| Europe And Other | $2M | N/A | N/A | N/A | N/A | N/A |
|---|
| North America | $2M | $3M | $3M | $433M | $343M | $292M |
|---|
| U | $369M | N/A | N/A | N/A | N/A | N/A |
|---|
| $389.52M |
| ($38.89M) |
| (9.08%) |
| 2019 | $428.41M | +$81.77M | +23.59% |
| 2018 | $346.64M | +$48.36M | +16.21% |
| 2017 | $298.28M | +$24.32M | +8.88% |
| 2016 | $273.96M | +$124.40M | +83.18% |
